Lung MRI to identify immune patterns in non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, single-center study will collect multiparametric MRI scans of the primary lung tumor in people with non-small cell lung cancer. MRI parameters will be combined to generate imaging "signatures" that investigators will compare with tumor biopsy results such as PD-L1 and histology to infer immune phenotypes. Eligible patients must have primary NSCLC (TNM 8th edition T≥T1c) with a biopsy adequate for PD-L1 quantification and a staging CT with uncertain nodal status. Patients with contraindications to MRI or gadolinium will be excluded and no investigational treatments are administered.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Primary NSCLC of the lung (TNM 8th edition T parameter ≥T1c)
* Biopsy examination of the primary tumor adequate at least for PDL-1 quantification
* Staging CT scan with uncertain N parameter and definite M parameter.

Exclusion Criteria:

* Absolute contraindications to magnetic resonance imaging or the administration of gadolinium-based contrast agents

Where it's running

• Fondazione IRCCS Policlinico San Matteo
  Pavia, Italy Recruiting

Study contacts

• Study coordinator: Chandra Bortolotto
• Email: c.bortolotto@smatteo.pv.it
• Phone: +390382503761

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Understanding what patients want from NSCLC treatment monitoring

  Researchers are testing how patients with non-small cell lung cancer feel about and prefer monitoring their symptoms during treatment, with input from patients, caregivers, and clinicians.

  Recruiting European Institute of Oncology · Milan, mI · NCT07909343

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• Cardiorespiratory fitness after lobectomy versus sublobar resection in NSCLC

  This study tests how different lung surgeries (lobectomy vs. sublobar resection) affect fitness levels after surgery in people with non-small cell lung cancer.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07841249

• CAIX-targeted PET/CT imaging in solid tumors

  Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT07833085

• NUT Project: Nutritional Support in Thoracic Cancer

  We’ll see if providing tailored nutrition guidance and assessment helps people with advanced lung cancer during their treatment.

  Recruiting Casa di Cura Dott. Pederzoli · Peschiera del Garda, Verona · NCT07817329

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.